Navigation Links
Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
Date:3/29/2009

ilatory anaerobic threshold (p=0.03). These effects were largely maintained at twelve months as well.

"This subgroup of the less severely impaired patients appeared to demonstrate an overall greater response rate that those in the control group," noted Dr. Alan Kadish, professor, Division of Cardiology, Feinberg School of Medicine, Northwestern University. "We are particularly encouraged by the findings in this subgroup of patients and look forward to focusing on this subgroup in our next study."

Yuval Mika, chief operating officer of Impulse Dynamics, commented, "The data show that CCM therapy has the potential to be an important new therapy for a greatly underserved group of heart failure patients. We have a clear pathway for further studies of CCM in this population which we believe will have favorable outcomes in the near future."

For a complete copy of the study, please contact Erich Sandoval at 917-497-2867 or esandoval@lazarpartners.com.

About Cardiac Contractility Modulation (CCM) Therapy

Cardiac Contractility Modulation is a new treatment for patients with heart failure. Unlike electrical signals delivered by other cardiac devices, such as pacemakers and implantable defibrillators, CCM signals do not initiate a heartbeat. Rather, CCM signals are intended to modify heart cell function in a manner that improves the strength of the heart muscle, therefore potentially enhancing the heart's overall pumping ability.

About the OPTIMIZER System

The OPTIMIZER System is CE Marked and commercially available in Europe and is currently under clinical investigation at major U.S. research and academic facilities. It consists of a pulse generator and conventional pacing leads which deliver the therapy to
'/>"/>

SOURCE Impulse Dynamics (U.S.A.) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
2. New CoMotion(R) Trials Software by General Dynamics Enables Rapid, Interactive Sharing of Real-time Data for Clinical Trials
3. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
4. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
7. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
8. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
9. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
10. Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
11. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)...  EndoChoice today announced the launch of its initial ... which will represent 25.6% of its outstanding common stock ... corporation in connection with the offering. The initial ... $15 and $17 per share. The underwriters for the ... up to an additional 937,500 shares of EndoChoice common ...
(Date:5/26/2015)... LONDON , May 26, 2015 ... that technology,s commercial potential ,What,s the future of ... and commercial predictions from 2015. Stay ahead there ... tests, you explore sales results, R&D, opportunities and ... visiongain shows you what,s possible for ...
(Date:5/26/2015)... , May 26, 2015  Array BioPharma ... its Chief Executive Officer, Ron Squarer , ... Conference in New York City. The public is welcome ... on the Array BioPharma website.Event: Jefferies 2015 Global ... 2015Time:1:30 p.m. Eastern Time Webcast: www.arraybiopharma.com  About Array ...
Breaking Medicine Technology:EndoChoice Announces Launch of Its Initial Public Offering 2Cell-Based Assays: World Industry and Market Prospects 2015-2025 2Cell-Based Assays: World Industry and Market Prospects 2015-2025 3Cell-Based Assays: World Industry and Market Prospects 2015-2025 4Cell-Based Assays: World Industry and Market Prospects 2015-2025 5Cell-Based Assays: World Industry and Market Prospects 2015-2025 6Cell-Based Assays: World Industry and Market Prospects 2015-2025 7
... WIRE)--Jun 25, 2007 - HepaLife Technologies, Inc.,(OTCBB: ... that new,data presented at an international influenza ... line outperforms,current cell technologies at replicating human ... step towards the production of,a cell-culture based ...
... of patients receiving highest dose,achieves A1c with ... /PRNewswire-FirstCall/ -- According to,findings presented today at ... Association (ADA) in Chicago, Illinois, the,investigational treatment ... analog under development by Novo Nordisk for ...
Cached Medicine Technology:HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 2HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 3HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 4HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 5HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 6Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 2Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 3Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 4
(Date:5/26/2015)... 2015 National Prevention Week , National ... It is supported by the Substance Abuse and Mental ... awareness of, and action about, substance abuse as well ... coalitions are encouraged to join in promoting prevention strategies, ... issues, and in building community partnerships. , The Voice ...
(Date:5/26/2015)... 2015 i2i Systems, the leader in ... than 15 years, has earned 2014 Patient Centered Medical ... Assurance (NCQA) for its flagship product i2iTracks , ... the work we have done to create healthier populations ... acknowledgement from NCQA once again,” said Janice Nicholson, co-founder ...
(Date:5/26/2015)... New York, NY (PRWEB) May 26, 2015 ... show for a good cause. "The photography show will connect ... difference in their lives.” For the last five years, Raul ... pictures to convey the notion that we are not bounded ... Quechua, a language spoken in Raul’s native country, Bolivia. The ...
(Date:5/26/2015)... 2015 Adenna, Inc ., worldwide ... excited to announce the launch of Enov8 ... made of polyethylene (PE) and approved by the U.S. ... , The Enov8 glove might look like ... mixing salads but our proprietary formula and production technology ...
(Date:5/26/2015)... Viejo, CA (PRWEB) May 26, 2015 ... styles for Final Cut Pro X . ... suspenseful to simple and elegantly styled text. , ... in seconds. , ProTrailer Network can easily complement any ... style desired and within seconds can make professional looking ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Takes Part in National Prevention Week 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 3Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 2Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 3Health News:A Photographer & Two Educational Organiazations Join to Make a Difference in Our Youth 2Health News:Enov8® Exam Glove by Adenna® Approved by U.S. FDA 2Health News:Developers at Pixel Film Studios Release ProTrailer Network for Final Cut Pro X 2
... A latest men’s health survey has revealed that men over ... in their 30s or 40s. Their level of satisfaction approximates ... interesting study are published in the February issue of BJU ... 185 Norway men ranged between 20 and 79 years of ...
... Tinnitus is a problem where people are plagued all round their ... from it since she was three. She describes it as the ... a metal spiral staircase. After 25 years later she says that ... an exhibition designer tells that it drives her crazy. Statistics show ...
... UK. The recent reports that many women will be barred from ... caused a lot of commotion among them. // ... 13,000 deaths are expected. But recently the Association of British Insurers ... genetic breast cancer tests. , But it was also ...
... logs, maintained by teenagers from age 13 to 17, ... personal information, //thus making them vulnerable to cyber stalking ... in the technology and social behavior program, will be ... American Association for the Advancement of Science in St. ...
... Immune cells destroy the myelin sheath that surrounds nerve ... myelin is very essential in transmitting the impulses across the ... the metals aluminium and iron in the urine of people ... said that MS could be linked to difficulty in processing ...
... that the euthanasia campaigner Dr Philip Nitschke does not possess ... ,The workshop informs participants of their legal rights about ending ... to be registered as a doctor to carry out his ... denies that he needs a licence. He faces a criminal ...
Cached Medicine News:Health News:50 Plus Men More Satisfied With Sex Life 2Health News:Tinnitus: a problem which is still ambiguous 2Health News:Health insurance in the future would depend on genetic test results 2Health News:Teens need to Exercise Caution While Using Online Blogs 2Health News:Aluminium and Iron Could Play a Vital Role in Multiple Sclerosis 2
... to remove a cast from an arm or ... patients are cut or burned by the cast ... professionals to remove any cast with confidence. This ... cuts and burns from the cast saw and ...
... choice plays an important part in ... particularly where reduced capsule formation, inflammation ... considerations. GORE-TEX Suture, a nonabsorbable, ePTFE ... characteristics sought by a variety of ...
... GORE-TEX ACUSEAL Cardiovascular Patch ... it to "seal" around penetrating ... bleeding by as much as ... with improved suture retention, multi-directional ...
... Vascular Grafts have met the challenges ... Recognized for exceptional performance and quality, ... renowned surgeons worldwide. These grafts require ... spread of infection, and ensure utmost ...
Medicine Products: